27 statements on adult airway management. One high certainty. The rest are expert consensus in guideline clothing. https://www.mattheneus.com/editorial/has-adult-airway-management-operating-theatre-label-recommendation-2026-09-23 #HTA #EvidenceSynthesis

Three modelling choices decide the severity weight: baseline utility, age extrapolation, shortfall method. 1.2 or 1.7. https://www.mattheneus.com/editorial/nice-severity-modifier-qaly-shortfall-utility-age-extrapolation-sensitivity-2026-09-21 #HTA #HealthEconomics

Cochrane endorses INSPECT-SR: 21 checks to screen randomised trials for trustworthiness before they enter your evidence base. https://www.mattheneus.com/editorial/cochrane-inspect-sr-trial-trustworthiness-tool-systematic-reviews-2026-09-24 #HTA #EvidenceSynthesis

Stacked systematic reviews can recycle the same primary studies into one AI accuracy claim. https://www.mattheneus.com/editorial/artificial-intelligence-accuracy-umbrella-review-primary-study-overlap-2026-09-24 #HTA #EvidenceSynthesis

The European Medicines Agency has opened consultation on clinical requirements for sickle cell disease medicines. https://www.mattheneus.com/editorial/ema-sickle-cell-disease-clinical-requirements-draft-guideline-consultation-2026-09-24 #HTA #RegulatoryAffairs

Fit-for-purpose and governance decisions have to be settled before data extraction starts in a registrational real-world evidence programme. https://www.mattheneus.com/editorial/real-world-evidence-registrational-programme-fit-for-purpose-governance-2026-09-24 #HTA #RWE

EU coordination group discontinues a joint clinical assessment over unmet dossier information requirements. https://www.mattheneus.com/editorial/european-commission-joint-assessment-discontinued-information-conformity-2026-09-16 #HTA #EvidenceSynthesis #RegulatoryAffairs

FDA approves a vial presentation of Garzulys insulin aspart, expanding delivery options for the fast-acting analogue. https://www.mattheneus.com/editorial/fda-garzulys-insulin-aspart-vial-presentation-approval-2026-09-15 #HTA #RegulatoryAffairs #Pharma

Reference prices drive a 69 percent cost gap between two European economic evaluations. https://www.mattheneus.com/editorial/reference-prices-cost-analysis-transferability-economic-evaluation-2026-09-24 #HTA #HealthEconomics #EvidenceSynthesis

"The abrupt swings from flood to drought has to stop" - yes!

Green spaces, nature not separated from humans, are crucial to climate resilience

#HortConf #HTA

Germany G-BA opens a statement procedure on rewritten quality rules for CAR-T cells and other advanced therapies. https://www.mattheneus.com/editorial/g-ba-atmp-quality-directive-car-t-annex-statement-procedure-2026-09-22 #HTA #RegulatoryAffairs #Pharma

MHRA authorises lurbinectedin maintenance for extensive-stage small cell lung cancer via international recognition route B. https://www.mattheneus.com/editorial/mhra-lurbinectedin-zepzelca-es-sclc-maintenance-authorisation-irp-route-b-2026-09-23 #HTA #RegulatoryAffairs

Rituximab vs ocrelizumab in relapsing MS: high certainty on lesions, very low on relapse. Wrong way round for a cost-substitution call. https://www.mattheneus.com/editorial/rituximab-ocrelizumab-design-stratified-evidence-cost-substitution-2026-09-23 #HTA #EvidenceSynthesis

Many cancer cost-effectiveness models claim validation, but the reporting rarely says what was actually checked. https://www.mattheneus.com/editorial/cancer-health-economic-model-validation-reporting-advishe-gap-2026-09-16 #HTA #HealthEconomics

Europe narrows ipidacrine indications after reviewing legacy evidence, underscoring why old evidence bases still demand modern scrutiny. #HTA #EvidenceSynthesis #RegulatoryAffairs https://www.mattheneus.com/editorial/ema-ipidacrine-indication-restrictions-legacy-evidence-review-2026-09-17

How does #HTA design influence pricing, reimbursement, and timely patient access across Latin America?

Join us to explore evolving HTA and access trends, with Argentina, Colombia, and Chile as illustrative case studies.

Register: https://ow.ly/3JcP50ZOsOL

Weight loss may offer real value in knee osteoarthritis, but UK decision-makers still lack a transferable economic evidence base. #HTA #HealthEconomics #RWE https://www.mattheneus.com/editorial/knee-osteoarthritis-weight-loss-economic-evidence-transferability-2026-09-22

Poland conditionally backed subcutaneous Vyvgart after reviewing direct and indirect comparative evidence. #HTA #EvidenceSynthesis #RegulatoryAffairs https://www.mattheneus.com/editorial/aotmit-vyvgart-subcutaneous-gmg-conditional-reimbursement-adapt-sc-bucher-2026-09-18

Six trials still leave T-tube use in liver-transplant biliary reconstruction without a clear practice conclusion. #HTA #EvidenceSynthesis #RegulatoryAffairs https://www.mattheneus.com/editorial/cochrane-t-tube-liver-transplant-biliary-reconstruction-six-trials-2026-09-22

Naloxone coverage is a marginal-return problem, not a universal target: local budgets and saturation thresholds shape value. #HTA #HealthEconomics #RWE https://www.mattheneus.com/editorial/naloxone-saturation-marginal-return-local-budget-thresholds-2026-09-22